Purpose Patients of non–small cell lung cancer (NSCLC) with brain metastases have limited
treatment options. High-dose erlotinib (HDE) and gefitinib (HDG) have been tried in the past …

Patients with non-small cell lung cancer (NSCLC) who develop leptomeningeal metastases
show significant clinical improvement following high-dose gefitinib therapy. Based on this …

Purpose Several cases have been reported in which central nervous system (CNS)
metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by …

Purpose We have treated patients with non-small-cell lung cancer (NSCLC) who developed
leptomeningeal metastases (LM) during gefitinib therapy, and then found symptomatic …

It has been demonstrated that erlotinib is effective in treating patients with brain metastasis
from non‑small‑cell lung cancer. However, the number of studies determining the erlotinib …

Limited treatment options are available for lung cancer with brain metastases. Recent
reports indicated that erlotinib and pemetrexed had synergistic effects in lung …

Background Although there have been several reports in which central nervous system
(CNS) metastases of non-small cell lung cancer (NSCLC) were improved by erlotinib …

Purpose Recent reports indicate that refractory central nervous system (CNS) metastases of
non-small cell lung cancer (NSCLC) are improved by high-dose gefitinib or erlotinib …

Abstract Lessons Learned This phase II trial evaluated the efficacy of erlotinib for patients
with non‐small cell lung cancer with leptomeningeal metastasis. The 17 cerebrospinal fluid …

Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such
as gefitinib and erlotinib, have high response and disease control rates in patients with …